Phase 3ACT DMD Clinical Trial

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) spiked higher by more than 7 percent on Friday, but are still lower by nearly 35 percent year-to-date. The company reported results from a Phase 3 ACT DMD clinical trial of Translarna on Thursday. Debjit Chattopadhyay of Roth Capital maintained a...